Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $122
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $105 to $122.
Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $105 to $122.